<DOC>
	<DOC>NCT01514240</DOC>
	<brief_summary>The purpose of this study is to evaluate the clinical efficacy of D9421-C 9 mg once daily compared to Mesalazine 1 g three times a day to patients with mild to moderate active Crohn's disease affecting ileum, ileocecal region and/or ascending colon as defined by a score of 180-400 on the Crohn's Disease Activity Index (CDAI) by assessment of the remission after 8-week treatment defined by a CDAI score of ≤ 150.</brief_summary>
	<brief_title>Phase III Study of D9421-C 9 mg in Patients With Active Crohn's Disease in Japan</brief_title>
	<detailed_description>A multicentre, double-blind, randomised, parallel-group, Phase III study to assess efficacy and safety of D9421-C 9 mg versus Mesalazine 3 g in patients with active Crohn's Disease (CD) in Japan</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>15 years of age or older Main active disease of the ileal, ileocecal region, and/or ascending colon If treated with partial nutrition treatment (≤1200 kcal/day) or if treated with azathioprine (≤2.0 mg/kg/day) or 6mercaptopurine (≤1.2 mg/kg/day), prior to randomisation until the study completion or discontinuation Ability to read, write and to fill a diary card and HRQL questionnaire Having mild to moderate active Crohn's disease, defined as CDAI score of 180400 at baseline Patient with CD lesion or status which may affect the evaluation of the efficacy (e.g. lesion only in the upper GI, active anorectal lesion, abscess formation, stenosis, fistulae, ostomy, short bowel or other uncontrolled concomitant disease) Patient who need any concomitant treatment for CD that may affect the assessment for efficacy of the study drug Patient who need any medication which is prohibited due to suspected influence to metabolism of the study drug Patient who is judged to be inadequate to participate in this study from the safety point of view Patient with wellfounded doubt about protocol violation</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>mild to moderate active Crohn's disease</keyword>
	<keyword>affecting ileum</keyword>
	<keyword>ileocecal region</keyword>
	<keyword>ascending colon</keyword>
	<keyword>score of 180-400 on the CDAI</keyword>
</DOC>